Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p. — Clinical Trial Site

70 Registered trials

22 Currently recruiting

Organisation

Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p.

Location

Wroclaw, Poland

Identifier

ORG-100044271

Address

Ul. Ul. Sliczna 13, 50-566, Poland

Departments

#40334: CITYCLINIC Przychodnia Lekarsko-Psychologiczna Matusiak sp. p.
#40845; Dermatology
0501: dermatology
1706:Dermatology
2691
40334: Dermatology
40334: NAP
CityClinic Przychodnia Lekarsko Psychologiczna
Cityclinic Przychodnia Lekarsko- Psychologiczna Matusiak Spółka Partnerska
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spolka Partnerska
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
CITYCLINIC PRZYCHODNIA LEKARSKOPSYCHOLOGICZNA MATUSIAK SPOLKA PARTNERSKA
Dermatology
Dermatology Venerology and Allergology
Faculty of Medicine, Wroclaw University of Science and Technology / Wroctaw / Poland
N/A
NA
Nie dotyczy
Nie dotyczy/N/A
not applicable/nie dotyczy
Private Practice
Przychodnia Lekarsko-Psychologiczna

Clinical trials at this site (70)

Search interface

Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised

2023-503522-40-00 Atopic Dermatitis 4
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moder… Pending

2023-508329-28-00 Atopic Dermatitis 4
A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending

2024-515439-31-00 Alopecia areata 5
Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria. Pending

2024-518786-10-01 Moderate to Severe Chronic Spontaneous Urticaria 4
A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending

2025-522831-33-00 Hidradenitis Suppurativa 4
BBT001 in Healthy Volunteers and in Adult Patients with Atopic Dermatitis Pending

2025-522918-23-00 Atopic Dermatitis 1
Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting

2025-521865-29-00 moderate-to-severe hidradenitis suppurativa 4 2026-04-30
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Moderate-to-severe hidradenitis suppurativa 4 2025-12-09
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Venous leg ulcer 5 2025-10-20
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Plaque Psoriasis 5 2026-04-28
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic… Recruiting

2025-522705-37-00 HIDRADENITIS SUPPURATIVA 4 2026-04-21
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Cold-Induced Urticaria and Symptomatic Dermographism 5 2026-04-13
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A Study of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis (BROADEN2) Recruiting

2025-522370-36-00 Moderate to Severe Atopic Dermatitis 4 2026-02-02
Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Hidradenitis suppurativa 4 2026-01-23
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on dise… Recruiting

2025-521684-12-00 Hidradenitis Suppurativa 4 2026-01-13
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A study to learn how the study drug bimekizumab works and how safe it is in treating moderate to severe hidradenitis suppurativa in children… Recruiting

2023-505323-31-00 Hidradenitis Suppurativa 5 2025-10-09
A 16-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g Compared to a Dummy Cream in Adult Subjects With Mild t… Recruiting

2024-518856-21-00 Mild to severe palmoplantar pustulosis 4 2025-08-28
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting

2024-514306-31-00 Pyoderma gangrenosum 5 2025-02-13